- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06900413
ESP vs. Exora -Blöcke für Analgesie in laparoskopischer Cholezystektomie
Vergleich der Wirksamkeit der Erector Spinae -Ebene (ESP) und der externen Schräg- und Rektusabdominis -Ebene (Exora) in laparoskopischer Cholezystektomie (Exora)
Patients undergoing laparoscopic cholecystectomy may experience moderate to severe postoperative pain. Effective postoperative analgesia enhances patient comfort and accelerates recovery. This study aims to compare the effects of Erector Spinae Plane (ESP) and External Oblique and Rectus Abdominis Plane (EXORA) blocks on postoperative pain management and analgesic consumption.
The study is designed as a prospective, randomized, double-blind trial. Patients will be randomly assigned to groups, and both practitioners and evaluators will be blinded to group assignments. Our hypothesis is that the EXORA block will provide superior analgesia and require less analgesic consumption compared to the ESP block. The results will be assessed in terms of postoperative pain management, patient comfort, and additional analgesic requirements.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Kütahya, Türkei (türkiye)
- Kütahya City Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Age between 18 and 65 years
Undergoing elective laparoscopic cholecystectomy
Classified as American Society of Anesthesiologists (ASA) physical status I to III
Providing written informed consent
Exclusion Criteria:
Known allergy or hypersensitivity to local anesthetics
Infection or skin lesions at the site of block application
Emergency surgical procedures
Refusal to participate in the study
Uncontrolled arterial hypertension
Uncontrolled diabetes mellitus
Mental retardation
Current use of antidepressant medications
Presence of metabolic disorders
Known bleeding diathesis
Morbid obesity (Body Mass Index > 40 kg/m²)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Group ESP
The ESP block will be performed approximately 30 minutes before general anesthesia induction following sedation and standard monitoring. All block procedures will be conducted under sterile conditions, with skin preparation using dermol (%70 Isopropyl Alcohol, %2 Chlorhexidine Gluconate) and the ultrasound probe covered with a sterile drape. |
Experienced anesthesiologists with at least five years of expertise in regional anesthesia will perform the blocks under ultrasound guidance. A 4.0-12.0 MHz linear ultrasound probe (Affiniti 50; Philips) will be used. The ESP block will be applied at the T8 level on the right side, using an in-plane approach, while the patient is in a sitting position. The probe will be placed 2-3 cm lateral to the vertebra in a sagittal position to visualize the erector spinae muscle and transverse processes. A 22G, 100 mm block needle (Stimuplex® Ultra, Braun, Germany) will be advanced in a craniocaudal direction. The correct needle position will be confirmed by injecting 0.5-1 mL of isotonic NaCl and observing the spread via hydrodissection. Finally, 0.3 mL/kg of 0.25% bupivacaine will be administered, ensuring cranial and caudal spread of the local anesthetic. |
|
Aktiver Komparator: Group EXORA
The EXORA block will be performed 30 minutes before general anesthesia induction, following sedation and standard monitoring. |
Experienced anesthesiologists with at least five years of expertise in regional anesthesia will administer the blocks under ultrasound guidance. A 4.0-12.0 MHz linear ultrasound probe will be placed laterally to the xiphoid process on the parasternal line in a sagittal position. The probe will be moved craniocaudally to identify the 6th rib and further advanced caudally to locate the 8th rib. Once the rectus abdominis muscle and 8th costal cartilage are identified, a 22G, 100 mm block needle will be used to administer 0.3 mL/kg of 0.25% bupivacaine. The correct spread of the local anesthetic will be confirmed via ultrasound. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Tramadol consumption
Zeitfenster: 12 and 24 hours
|
Total tramadol used in the first 12 and 24 hours postoperatively. |
12 and 24 hours
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Visual Analog Scale (VAS) for Pain Assessment
Zeitfenster: 30 minutes, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours after surgery
|
Postoperative pain will be assessed using the Visual Analog Scale (VAS), which ranges from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate a worse outcome (more pain). Units on a scale (0-10) |
30 minutes, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours after surgery
|
|
Pinprick Sensory Block Test Results
Zeitfenster: 10 minutes, 20 minutes, and 30 minutes after the block, and 30 minutes after surgery
|
Sensory block efficacy will be evaluated using the pinprick test at specified time intervals. The presence or absence of sensory block will be recorded. Binary (Block present / Block absent) |
10 minutes, 20 minutes, and 30 minutes after the block, and 30 minutes after surgery
|
|
Nausea and Vomiting Score (NVS)
Zeitfenster: Within 24 hours after surgery
|
Postoperative nausea and vomiting will be evaluated using the Nausea and Vomiting Scale (NVS), which includes:
|
Within 24 hours after surgery
|
|
Ramsay Sedation Scale (RSS)
Zeitfenster: Within 24 hours after surgery
|
Postoperative sedation will be assessed using the Ramsay Sedation Scale (RSS), which includes:
|
Within 24 hours after surgery
|
|
Additional Analgesic Consumption
Zeitfenster: Within 24 hours after surgery
|
The total amount of additional analgesics administered postoperatively will be recorded. Milligrams (mg) |
Within 24 hours after surgery
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Total Antiemetic Consumption
Zeitfenster: Within 24 hours after surgery
|
The total amount of antiemetic medication administered within 24 hours postoperatively will be recorded. Milligrams (mg) |
Within 24 hours after surgery
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Aycan KURTARANGİL DOĞAN, Kütahya City Hospital
- Hauptermittler: Ali Kaynak, Kütahya City Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- KSH-01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .